5 September 2017 - The Department of Health has asked NICE to produce guidance on use of ixazomib citrate (Ninlaro) in combination with lenalidomide and dexamethasone for patients with multiple myeloma in the NHS in England.

Ixazomib, with lenalidomide and dexamethasone, is not recommended within its marketing authorisation for treating multiple myeloma in adults who have already had at least one therapy.

The main clinical trial is ongoing and limited data are available. It is not yet clear whether ixazomib prolongs life compared with the current treatment for people who have had two or three therapies (lenalidomide plus dexamethasone).

Read NICE Appraisal Consultation Document for ixazomib citrate